CSLLY
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- CSL reports positive Phase 3b topline results supporting planned pediatric label expansion for ANDEMBRY in hereditary angioedemaJul 27, 2026
- CSL Canada announces first Canadian patient receives HEMGENIX gene therapy for hemophilia BMay 20, 2026
- VarmX partners with CSL in strategic collaboration and option agreement to develop novel investigational coagulation treatmentSep 16, 2025
- Health Canada authorizes CSL's ANDEMBRY® (garadacimab) as once-monthly treatment for hereditary angioedemaAug 8, 2025